指南与共识腹部CT

结肠镜检查的影像学替代方案:CT结肠成像与结肠胶囊内镜——欧洲胃肠道内镜学会(ESGE)与欧洲胃肠道和腹部放射学会(ESGAR)指南2020年更新

Imaging alternatives to colonoscopy: CT colonography and colon capsule. European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline - Update 2020.
指南 / 共识 · Endoscopy · 2020-10-26

该指南由ESGE与ESGAR联合制定,推荐CT结肠成像(CTC)作为诊断结直肠肿瘤的首选放射学检查(强推荐,高质量证据),不推荐钡剂灌肠;结肠镜检查不完整时推荐CTC(最好当日或次日),在具备结肠胶囊内镜(CCE)专长和条件的中心可考虑CCE(弱推荐,低质量证据)。指南还就不完全结肠镜、警报症状、筛查、监测及禁忌证等情形给出了推荐。

要点

  • CTC是诊断结直肠肿瘤的首选放射学检查(强推荐,高质量证据),不推荐钡剂灌肠(强推荐,高质量证据)。
  • 结肠镜检查不完整时推荐CTC(最好当日或次日),时机取决于内镜与放射学的跨学科决策(强推荐,低质量证据)。
  • CTC或CCE检出至少一个≥6 mm息肉时应转诊行内镜下息肉切除术(强推荐,中等质量证据)。

核心结论

  • ESGE/ESGAR推荐CTC作为诊断结直肠肿瘤的首选放射学检查(强推荐,高质量证据),不推荐钡剂灌肠(强推荐,高质量证据)。
  • 结肠镜检查不完整时推荐CTC(最好当日或次日),时机取决于内镜与放射学因素的跨学科决策(强推荐,低质量证据)。
  • 在具备CCE专长和条件的中心,结肠镜检查不完整时可考虑CCE(最好当日或次日)(弱推荐,低质量证据)。

研究设计与样本

  • 该指南由欧洲胃肠道内镜学会(ESGE)与欧洲胃肠道和腹部放射学会(ESGAR)联合制定,为2020年更新版。
  • 原文未报告检索范围、纳入文献数量及证据分级方法的具体细节。

诊断标准与关键数值

  • 结肠镜检查禁忌或不可行时,对警报症状患者推荐CTC作为可接受且敏感性相当的替代方案(强推荐,高质量证据);因缺乏直接证据,不推荐CCE用于此情形(极低质量证据)。
  • 对非警报症状患者,推荐CTC作为结肠镜检查的可接受替代方案(强推荐,高质量证据);在有条件的中心建议可考虑CCE(弱推荐,低质量证据)。
  • 无组织性FIT结直肠筛查项目时,推荐CTC作为结直肠癌筛查选项,需充分告知受检者检查特征、获益与风险,并取决于当地服务与患者相关因素(强推荐,高质量证据);不建议CCE作为结直肠癌一线筛查试验(弱推荐,低质量证据)。
  • 组织性人群筛查项目中FOBT或FIT阳性且结肠镜检查不完整或不可行时,推荐CTC(强推荐,中等质量证据);根据可及性也建议使用CCE(弱推荐,中等质量证据)。
  • 结直肠癌治愈性切除术后监测,仅对结肠镜检查禁忌或不可行患者建议使用静脉对比剂增强CTC(弱推荐,低质量证据);该情形下证据不足以推荐CCE(极低质量证据)。

临床应用与阅片要点

  • 高危息肉息肉切除术后监测,仅当结肠镜检查不可行时建议CTC(弱推荐,低质量证据);息肉切除术后监测中证据不足以推荐CCE(极低质量证据)。
  • 急性结肠炎症及近期接受结直肠手术患者不推荐CTC,须等待多学科评估(强推荐,低质量证据)。
  • CTC或CCE检出至少一个≥6 mm息肉时应转诊行内镜下息肉切除术(强推荐,中等质量证据)。
  • CTC检出6–9 mm病变若患者因个人选择、合并症和/或晚期肿瘤低风险未行息肉切除术,可临床上考虑随访CTC(强推荐,中等质量证据)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

1: ESGE/ESGAR recommend computed tomographic colonography (CTC) as the radiological examination of choice for the diagnosis of colorectal neoplasia.Strong recommendation, high quality evidence.ESGE/ESGAR do not recommend barium enema in this setting.Strong recommendation, high quality evidence. 2: ESGE/ESGAR recommend CTC, preferably the same or next day, if colonoscopy is incomplete. The timing depends on an interdisciplinary decision including endoscopic and radiological factors.Strong recommendation, low quality evidence.ESGE/ESGAR suggests that, in centers with expertise in and availability of colon capsule endoscopy (CCE), CCE preferably the same or the next day may be considered if colonoscopy is incomplete.Weak recommendation, low quality evidence. 3: When colonoscopy is contraindicated or not possible, ESGE/ESGAR recommend CTC as an acceptable and equally sensitive alternative for patients with alarm symptoms.Strong recommendation, high quality evidence.Because of lack of direct evidence, ESGE/ESGAR do not recommend CCE in this situation.Very low quality evidence.ESGE/ESGAR recommend CTC as an acceptable alternative to colonoscopy for patients with non-alarm symptoms.Strong recommendation, high quality evidence.In centers with availability, ESGE/ESGAR suggests that CCE may be considered in patients with non-alarm symptoms.Weak recommendation, low quality evidence. 4: Where there is no organized fecal immunochemical test (FIT)-based population colorectal screening program, ESGE/ESGAR recommend CTC as an option for colorectal cancer screening, providing the screenee is adequately informed about test characteristics, benefits, and risks, and depending on local service- and patient-related factors.Strong recommendation, high quality evidence.ESGE/ESGAR do not suggest CCE as a first-line screening test for colorectal cancer.Weak recommendation, low quality evidence. 5: ESGE/ESGAR recommend CTC in the case of a positive fecal occult blood test (FOBT) or FIT with incomplete or unfeasible colonoscopy, within organized population screening programs.Strong recommendation, moderate quality evidence.ESGE/ESGAR also suggest the use of CCE in this setting based on availability.Weak recommendation, moderate quality evidence. 6: ESGE/ESGAR suggest CTC with intravenous contrast medium injection for surveillance after curative-intent resection of colorectal cancer only in patients in whom colonoscopy is contraindicated or unfeasibleWeak recommendation, low quality evidence.There is insufficient evidence to recommend CCE in this setting.Very low quality evidence. 7: ESGE/ESGAR suggest CTC in patients with high risk polyps undergoing surveillance after polypectomy only when colonoscopy is unfeasible.Weak recommendation, low quality evidence.There is insufficient evidence to recommend CCE in post-polypectomy surveillance.Very low quality evidence. 8: ESGE/ESGAR recommend against CTC in patients with acute colonic inflammation and in those who have recently undergone colorectal surgery, pending a multidisciplinary evaluation.Strong recommendation, low quality evidence. 9: ESGE/ESGAR recommend referral for endoscopic polypectomy in patients with at least one polyp ≥ 6 mm detected at CTC or CCE.Follow-up CTC may be clinically considered for 6 - 9-mm CTC-detected lesions if patients do not undergo polypectomy because of patient choice, comorbidity, and/or low risk profile for advanced neoplasia.Strong recommendation, moderate quality evidence.

来源:Endoscopy,查看原文。版权归原作者所有。

引用

  1. Spada C, Hassan C, Bellini D, et al. Imaging alternatives to colonoscopy: CT colonography and colon capsule. European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline - Update 2020. Endoscopy. 2020. PMID: 33105507. doi:10.1055/a-1258-4819

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。